Corrine Savill Cullinan Oncology, Inc. (CGEM) insider trading activity

Corrine Savill is Chief Business Officer of Cullinan Oncology, Inc.. Currently has a direct ownership of 240,990 shares of CGEM, which is worth approximately $2.08 Million. The most recent transaction as insider was on Feb 19, 2025, when has been sold 37,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 241K

18.43% 3M change

18.43% 12M change

Total Value Held $2.08 Million

Corrine Savill Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 19 2025	BUY Grant, award, or other acquisition	-	37,500 Added 13.47%	240,990 Common Stock
Feb 22 2024	BUY Grant, award, or other acquisition	-	37,500 Added 15.56%	203,490 Common Stock
Feb 01 2024	SELL Open market or private sale	$647,200 $16.18 p/Share	40,000 Reduced 19.42%	165,990 Common Stock
Feb 01 2024	BUY Exercise of conversion of derivative security	$172,000 $4.3 p/Share	40,000 Added 16.26%	205,990 Common Stock
Jan 29 2024	SELL Open market or private sale	$563,600 $14.09 p/Share	40,000 Reduced 19.42%	165,990 Common Stock
Jan 29 2024	BUY Exercise of conversion of derivative security	$172,000 $4.3 p/Share	40,000 Added 16.26%	205,990 Common Stock
Jan 23 2024	SELL Open market or private sale	$265,597 $12.46 p/Share	21,316 Reduced 11.38%	165,990 Common Stock
Jan 23 2024	BUY Exercise of conversion of derivative security	$91,658 $4.3 p/Share	21,316 Added 10.22%	187,306 Common Stock
Jan 22 2024	SELL Open market or private sale	$226,076 $12.1 p/Share	18,684 Reduced 10.12%	165,990 Common Stock
Jan 22 2024	BUY Exercise of conversion of derivative security	$62,603 $4.3 p/Share	14,559 Added 7.31%	184,674 Common Stock
Feb 17 2023	BUY Grant, award, or other acquisition	-	20,500 Added 10.75%	170,115 Common Stock
Jul 19 2022	SELL Open market or private sale	$227,661 $15.22 p/Share	14,958 Reduced 9.09%	149,615 Common Stock
Jul 18 2022	SELL Open market or private sale	$75,933 $15.06 p/Share	5,042 Reduced 2.97%	164,573 Common Stock
Jul 11 2022	SELL Open market or private sale	$543,600 $13.59 p/Share	40,000 Reduced 19.08%	169,615 Common Stock
Feb 11 2022	BUY Grant, award, or other acquisition	-	16,500 Added 7.3%	209,615 Common Stock

Corrine Savill

Chief Business Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CGEM shares.

Notify only if

Value

Insider Trading

Get notified when an Cullinan Oncology, Inc. insider buys or sells CGEM shares.

Notify only if

Operation

Value

Type

News

Receive news related to Cullinan Oncology, Inc.

Track Activities on CGEM

Account